Diabetes Research and Clinical Practice - Volume 120 - Supplement 1

PD-119

Eating habits of 84 diabetic out-patients with increased HbA1c

level or body weight in SGLT2 inhibitors treatment

Ayae KUDARA

, Takahiro TOSAKI

*, Michiko NOZAWA

Yoshie MURASE

, Rie TAKATE

, Yoko KYONO

Shizuko KIDOKORO

, Tomoyo HAYASAKI

, Masaki KONDO

Akemi INAGAKI

, Hideki KAMIYA

, Jiro NAKAMURA

TDE

Healthcare Corporation TOSAKI Clinic for Diabetes and

Endocrinology,

Division of Diabetes, Department of Internal

Medicine, Aichi Medical University School of Medicine,

Japanese Red

Cross Nagoya Daini Hospital, Japan

Objective:

We investigated eating habits of diabetic patients

with SGLT2 inhibitors treatment. And we studied about

correlations between eating habits and changes in HbA1c

level or body weight.

Subjects:

132 type 2 diabetic out-patients with 6-month with

SGLT2 inhibitors treatment.

Method:

We conducted a questionnaire to 84 cases. We ask

some questions in a field interview survey about that how

many times they had meals, howmuch staple food (e.g. bread,

rice) or vegetables they had, if they had some snacks or

not (e.g. Western-style confectioneries, Japanese confec-

tioneries, vegetable juice, beverages including high-fructose

corn syrup), if they eat at regular times, and if they had a meal

after 9 p.m. We investigated relations among these question-

naire results, HbA1c level, body weight and visceral fat mass

area.

Result:

Both HbA1c and body weight did not improve in 12% of

entire cases with SGLT2 inhibitors treatment. In a group with

HbA1c level elevation, the patients tended to eat at irregular

times. In a group with weight increase, the patients tended to

drink a beverage including high-fructose corn syrup, eat at

irregular times, and have a meal after 9 p.m. Also, the number

of the times they had a meal was less than 3, or they didn

’

have much amount of staple food or vegetables. On the other

hand, some patients whose body weight decreased said that

they always had chewed gum or drunk some water when they

had felt hungry. And they also said that they had stopped

eating before they had felt full, and had had dinner earlier

than usual.

Conclusion:

We considered that eating habits might be

associated with effectiveness of SGLT2 inhibitors. It might be

important for medical staffs to ask patients about their eating

habits frequently and give advice suited for individual patients

on them.

PD-120

Linagliptin reduces the diabetic nephropathy score, DN_Score,

in patients with T2DM and microalbuminuria: A predefined

substudy from the MARLINA-T2D

™

trial

Tzu-Ling TSENG

, Wei-Ya LIN

, Hsiang-Chi WANG

Sandra THIEMANN

, Maximilian VON EYNATTEN

Lee-Ming CHUANG

Bio Preventive Medicine Corp., Taiwan;

Boehringer Ingelheim Pharma GmbH & Co. KG, Germany;

National

Taiwan University Hospital, Taiwan

Background and aims:

In the MARLINA-T2D

™

study, we

applied a novel urinary biomarker panel, DNlite, to investigate

the renal effects of Linagliptin in patients with type 2 diabetes.

Materials and methods:

The diabetic nephropathy score

(DN_Score) is a composite score built from fitting

several urinary biomarkers in DNlite to a statistical model,

that correlates highly with the stage of diabetic nephropathy. It

has been validated in previous studies. MARLINA-T2D

™

is a

Phase IIIb, multicenter, multinational, randomized, double-

blind, placebo controlled, parallel group study to evaluate the

glycemic and renal efficacy of once daily administration of

linagliptin 5 mg for 24 weeks in type 2 diabetes patients, with

micro- or macroalbuminuria (30

–

3000 mg/g creatinine) on top

of current treatment with Angiotensin Converting Enzyme

inhibitor or Angiotensin Receptor Blocker. The percent change

from baseline in DN_Score at week 24 was analyzed by an

analysis of covariance (ANCOVA) based on the full analysis set,

with baseline DN_Score as the prespecified covarite. Several

other covariates were also explored.

Results:

Out of 360 patients in MARLINA-T2D

™

, urine samples

for this substudy were available for 139 and 148 individuals

for PBO and linagliptin, respectively. Linagliptin significantly

reduced DN_Score from Week 0 to Week 24 vs PBO in patients

with type 2 diabetes and UACR < 300 mg/g creatinine at

baseline, p < 0.05. No effect was seen in patients with UACR

≥

300 mg/g creatinine at baseline.

Conclusion:

In patients with type 2 diabetes and microalbu-

minuria linagliptin significantly improved a diabetic nephro-

pathy panel, as assessed by DN_Score. The renal effects of

linagliptin in early stages of glomerular damage warrant

further research.

PD-121

Incretin-based therapy has better glycemic sustainability and

less variability in patients with diabetes on stable anti-diabetic

medications

Bing Ru GAU

, Pin Fan CHEN

*, Wei Cheng LIAN

Ting Chang CHEN

Division of Endocrinology and Metabolism,

DaLin Tzuchi General Hospital, Taiwan

Aims:

Incretin-based therapy was ever proved more effective

in lowering glycated hemoglobin (HbA1c) in Asian group. This

study aimed to investigate the glycemic sustainability and

variability effects of incretin-based therapy in type 2 diabetic

patients in real-world practice.

Methods:

A total 623 outpatients with type 2 diabetes mellitus

(mean age, 64.7 years), received stable fixed-dose combina-

tions oral anti-diabetic agents (OADs) without any adjustment

for at least 6months were enrolled during January to April 2015

after patients who used insulin were excluded.

Those patients were divided into two groups: those who

treated with incretin-based therapy (n = 391) and others (n =

232). The medical records were reviewed and laboratory tests

were collected and analyzed. The Analyses of Covariance

with adjustment of age, gender, years of diabetes diagnosis,

renal function, baseline HbA1c and numbers of OAD

’

categories was using to compare glycemic control between

two groups.

Results:

The baseline HbA1c (mean ± standard deviation) of

incretin-based group and comparison group were 7.1 ± 0.9%

and 7.2 ± 1.0%, respectively (p = 0.211). The group of incretin-

based therapy revealed better glycemic control in the following

–

month periods. The average HbA1c (marginal mean ±

standard error) between groups was 6.9 ± 0.4% and 7.3 ± 0.5%

(p < 0.001) in 3 months and 7.0 ± 0.4% and 7.2 ± 0.5% (p = 0.024)

in 6 month. In addition, the statistic variances of HbA1c in

the following period in two groups were 0.28 ± 0.49 and

0.367 ± 0.90, respectively (p = 0.007).

Conclusion:

In this study, incretin-based therapy was shown

the effects of better glycemic sustainability and less variability

in diabetic patients on stable anti-diabetic medications in real-

world practice.

PD-122

A real world experience of long-acting GLP-1 receptor agonists

in a medical center in southern of Taiwan

Chun-Yi YANG

Division of Endocrinology & Metabolism,

Department of Internal Medicine, Chi-Mei Medical Center, Taiwan

Objective:

To determine whether treatment with long acting

agonists of glucagon-like peptide-1 receptor (GLP-1R)-

Liraglutide result in weight loss and glycemic control in real

world practice. We presented our experience of Long-acting

GLP-1 receptor agnists (Liraglutide) in treating of overweight

and obese T2DM patients

Poster Presentations / Diabetes Research and Clinical Practice 120S1 (2016) S65

–

S211

S129